Early Use of Zoledronic Acid (Zometa) in Men with Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).

We have long known that Zoledronic Acid (Zometa) decreases a man’s risk of developing skeletal-related events (SREs) in men with castration-resistant advanced prostate cancer (CRPC) and bone metastases. In a phase III study that evaluated efficacy and safety of earlier treatment with Zometa in men with advanced prostate cancer which is still castration-sensitive found that [...]

AUA 2012 – The Absence of Goal Setting in the Dialogue between Men with Advanced Prostate Cancer and their Doctors

What are our goals as advanced prostate cancer survivors and what are the goals of our oncologists? Often they are not the same! This misalignment between our expectations and those of our clinicians is common, but inexcusable. These issues become clear when we look at issues surrounding our quality of life. The treatments for advanced [...]

Prostate Cancer SATURN Trial, a Phase 3 Trial in Men with Metastatic Prostate Cancer

A new phase 3, registration trial has been announced by OncoGenex Pharmaceuticals, Inc. of its investigational drug custirsen sodium (OGX-011/TV-1011). The trial, for men with metastatic castrate resistant prostate cancer (mCRPC) is referred to as the Prostate Cancer SATURN Trial. This randomized, controlled, trial will include approximately 50 cancer centers and is planned to enroll [...]

Go to Top